Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Feb 7:4:3.
doi: 10.1186/s40662-017-0068-8. eCollection 2017.

Pharmacological treatments of presbyopia: a review of modern perspectives

Antonio Renna  1   2 , Jorge Luciano Alió  3   4 , Luis Felipe Vejarano  5   6
Affiliations
Review

Pharmacological treatments of presbyopia: a review of modern perspectives

Antonio Renna et al. Eye Vis (Lond). .

Erratum in

Abstract

Introduction: Presbyopia affects people from the 4th decade of life and is characterized by accommodative loss that leads to negative effects on vision-targeted health-related quality of life. A non-invasive pharmacological treatment providing near-lenses independence would be a truly groundbreaking approach in the treatment of presbyopia. The purpose of this review is to analyze the emerging pharmacological solutions proposed to address presbyopia.

Results: Several ophthalmic eye drops compounds solutions have been described in peer-reviewed papers or presented in ophthalmological tabloids and congresses. Each topical treatment deals with drug combinations aimed to modify one or more factors involved in the accommodative process and have been proposed to be instilled either monocularly or binocularly. It remains unclear how much each drug in the final combined form is involved in the achievement of the outcome and contributes to it.

Conclusion: Despite the lack of a completely well understood mechanism, pharmacological control of presbyopia seems to be a possible and very attractive alternative for presbyopic patients. The studies mentioned in this review are to be considered pilot investigations as they involve either a small number of subjects or are single case series. Complete studies are needed to confirm which will be the more effective pharmacological compound for the treatment of presbyopia.

Keywords: Accommodation; Ageing; Eyedrops; Glasses; Multifocality; Near vision; Pharmacological therapy; Presbyopia.

PubMed Disclaimer

References

    1. McDonnell PJ, Lee P, Spritzer K, Lindblad AS, Hays RD. Associations of presbyopia with vision-targeted health-related quality of life. Arch Ophthalmol. 2003;121(11):1577–81. doi: 10.1001/archopht.121.11.1577. - DOI - PubMed
    1. Charman WN. Developments in the correction of presbyopia II: surgical approaches. Ophthalmic Physiol Opt. 2014;34(4):397–426. doi: 10.1111/opo.12129. - DOI - PubMed
    1. Abdelkader A. Improved presbyopic vision with miotics. Eye Contact Lens. 2015;41(5):323–7. doi: 10.1097/ICL.0000000000000137. - DOI - PubMed
    1. Renna A, Vejarano LF, De la Cruz E, Alió JL. Pharmacological treatment of presbyopia by novel binocularly instilled eye drops: a pilot study. Ophthalmol Ther. 2016;5(1):63–73. doi: 10.1007/s40123-016-0050-x. - DOI - PMC - PubMed
    1. Benozzi J, Benozzi G, Orman B. Presbyopia: a new potential pharmacological treatment. Med Hypothesis Discov Innov Ophthalmol. 2012;1(1):3–5. - PMC - PubMed